Introduction
Mid Pharma companies are EU/US based pharmaceutical companies with 2005 annual revenues of <$10bn. An integral component of the Mid Pharma business model is securing access to promising new drugs through in-licensing and acquisition.

Scope
Segmentation of the Mid Pharma market by key attributes including revenue size, therapy area and geographic focus
Analysis of how dependent each Mid Pharma company is on externalization to support current portfolios
Examination of which types of externalization strategy are most popular in the Mid Pharma peer set
Case studies of how domestic players such as Menarini and Almirall are operating as conduits to the highly fragmented local markets of Europe
Highlights
Segmentation of the PharmaVitae Mid Pharma peer set of 22 companies into 5 clusters the 'Big 6', CNS-focus, CV-focus, small domestic and 'multi-business unit' clusters.

Insight into the deep CNS cardiovascular therapeutic axis that runs through Mid Pharma with CNS (Lundbeck, Forest and Shire) and CV-focused (Servier, King, Menarini and Schwarz) players at either end of the spectrum with the 'Big 6' players located in the middle range, addressing a broad range of therapy areas.

Analysis of how the level of externalization dependency varies within Mid Pharma, from highly committed in-licensors such as Forest to internally-sufficient operations such as Servier.

Reasons to Purchase
Understand why the majority of Mid Pharma companies are committed to populating their portfolios by in-licensing and acquisition
Identify which companies are appropriate licensing targets on the basis of their 'fit' according to their scale, therapeutic and geographic focus
Learn which types of externalization strategy are responsible for the largest influx of product revenues to Mid Pharma